Given their multifaceted pharmacological properties (anti-inflammatory, neurotrophic/neuroprotective), PPAR pathways have also attracted considerable attention as potential therapeutic targets, as well as risk factors, in various neurological disorders, including AD, multiple sclerosis (MS), Parkinson’s Disease (PD), and epilepsy [43,44,79,132,133] (Table 1). The gene discussed is PPARA; the disease is nervous system disorder.